DOCSLIB.ORG

Patient-Formulary.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient-Formulary.Pdf Sandwell and West Birmingham Hospitals NHS Trust Sandwell and West Birmingham Clinical Commissioning Group Formulary The drugs contained in the formulary of Sandwell and West Birmingham Hospitals Trust are listed below. NICE considers that the benefits of a local formulary include • improving patient outcomes by optimising the use of medicines; • supporting the inclusion of patient factors in decision-making about medicines; • improving local care pathways; • improving collaboration between clinicians and commissioners; • improving quality by reducing inappropriate variations in clinical care; • improving quality through access to cost-effective medicines; • supporting the supply arrangements of medicines across a local health economy; • supporting financial management and expenditure on medicines across health communities; • supporting prescribers to follow guidance published by professional regulatory bodies in relation to medicines and prescribing. Drugs marked in black text are available for general use and may be prescribed by any prescriber in the Trust Drugs marked in orange as “restricted” are available for use in restricted circumstances; they may be restricted to certain specialties, or for treating certain diseases, or for use when first-line treatment has not worked. Where clinically appropriate, prescribing of restricted drugs may be passed to primary care on the advice of a specialist. Drugs which are approved by NICE in a technology appraisal are available for use in the Trust. All other drugs are available on Consultant request provided the request is authorized by a medical director or an officer of the Drug and Therapeutics committee. This formulary was published on 8th January 2014 Formulary Sec tion Title Status 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and simeticone->Aluminium- and magnesium-containing antacids ALUMINIUM HYDROXIDE On Formulary 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and simeticone->Aluminium- and magnesium-containing antacids MAGNESIUM TRISILICATE On Formulary 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and simeticone->Aluminium- and magnesium-containing antacids->ALUMINIUM HYDROXIDE Co-magaldrox On Formulary 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and simeticone->Aluminium- and magnesium-containing antacids->ALUMINIUM HYDROXIDE->Co- magaldrox Maalox® On Formulary 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and simeticone->Aluminium- and magnesium-containing antacids->MAGNESIUM TRISILICATE Magnesium Trisilicate Mixture, BP On Formulary 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and simeticone->Simeticone alone Infacol® Restricted 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates and proprietary indigestion preparations->Alginate raft-forming oral suspensions Peptac® On Formulary 1 Gastro-intestinal system->1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates and proprietary indigestion preparations->Other compound alginate preparations Gaviscon Infant® Restricted 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility Motility stimulants On Formulary 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility->Antimuscarinics ATROPINE SULFATE On Formulary 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility->Antimuscarinics HYOSCINE BUTYLBROMIDE On Formulary 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility->Antimuscarinics->ATROPINE SULFATE Atropine On Formulary 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility->Antimuscarinics->HYOSCINE BUTYLBROMIDE Buscopan® On Formulary 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility->Other antispasmodics MEBEVERINE HYDROCHLORIDE On Formulary 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility->Other antispasmodics PEPPERMINT OIL On Formulary 1 Gastro-intestinal system->1.2 Antispasmodics and other drugs altering gut motility->Other antispasmodics->MEBEVERINE HYDROCHLORIDE Mebeverine Hydrochloride On Formulary 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.1 H2-receptor antagonists RANITIDINE On Formulary 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.1 H2-receptor antagonists->RANITIDINE Ranitidine On Formulary 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.4 Prostaglandin analogues MISOPROSTOL Restricted This formulary was published on 8th January 2014 Formulary Sec tion Title Status 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.5 Proton pump inhibitors LANSOPRAZOLE On Formulary 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.5 Proton pump inhibitors OMEPRAZOLE Restricted 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.5 Proton pump inhibitors->LANSOPRAZOLE Lansoprazole On Formulary 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.5 Proton pump inhibitors->LANSOPRAZOLE Zoton® Restricted 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.5 Proton pump inhibitors->OMEPRAZOLE Omeprazole On Formulary 1 Gastro-intestinal system->1.3 Antisecretory drugs and mucosal protectants->1.3.5 Proton pump inhibitors->OMEPRAZOLE Losec® Restricted 1 Gastro-intestinal system->1.4 Acute diarrhoea->1.4.2 Antimotility drugs CODEINE PHOSPHATE On Formulary 1 Gastro-intestinal system->1.4 Acute diarrhoea->1.4.2 Antimotility drugs LOPERAMIDE HYDROCHLORIDE On Formulary 1 Gastro-intestinal system->1.4 Acute diarrhoea->1.4.2 Antimotility drugs MORPHINE On Formulary 1 Gastro-intestinal system->1.4 Acute diarrhoea->1.4.2 Antimotility drugs->LOPERAMIDE HYDROCHLORIDE Imodium® On Formulary 1 Gastro-intestinal system->1.4 Acute diarrhoea->1.4.2 Antimotility drugs->LOPERAMIDE HYDROCHLORIDE Loperamide On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates MESALAZINE On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates SULFASALAZINE On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates BALSALAZIDE SODIUM Restricted 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates->BALSALAZIDE SODIUM Colazide® Restricted 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates->MESALAZINE Asacol® On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates->MESALAZINE Asacol® MR On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates->MESALAZINE Pentasa® On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates->MESALAZINE Salofalk® On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.1 Aminosalicylates->SULFASALAZINE Sulfasalazine On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.2 Corticosteroids PREDNISOLONE On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.2 Corticosteroids BUDESONIDE Restricted 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.2 Corticosteroids->PREDNISOLONE->Rectal preparations Predsol® On Formulary 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.3 Drugs affecting the immune response AZATHIOPRINE Restricted 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.3 Drugs affecting the immune response->Cytokine modulators ADALIMUMAB Restricted 1 Gastro-intestinal system->1.5 Chronic bowel disorders->1.5.3 Drugs affecting the immune response->Cytokine modulators- >INFLIXIMAB Preparations Restricted This formulary was published on 8th January 2014 Formulary Sec tion Title Status 1 Gastro-intestinal system->1.6 Laxatives->1.6.1 Bulk-forming laxatives ISPAGHULA HUSK On Formulary 1 Gastro-intestinal system->1.6 Laxatives->1.6.1 Bulk-forming laxatives METHYLCELLULOSE On Formulary 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives DOCUSATE SODIUM On Formulary 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives GLYCEROL On Formulary 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives SENNA On Formulary 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives SODIUM PICOSULFATE On Formulary 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives DANTRON Restricted 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives- With docusate sodium (as co- >DANTRON danthrusate) Restricted 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives- With poloxamer ?188? (as co- >DANTRON danthramer) Restricted 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives- >DANTRON->With docusate sodium (as co-danthrusate) Co-danthrusate Restricted 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives- >DANTRON->With poloxamer ?188? (as co-danthramer) Co-danthramer Restricted 1 Gastro-intestinal system->1.6 Laxatives->1.6.2 Stimulant laxatives- >GLYCEROL Glycerol Suppositories, BP On Formulary 1 Gastro-intestinal system->1.6 Laxatives->1.6.2
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • E001466.Full.Pdf
    Editorial BMJ Glob Health: first published as 10.1136/bmjgh-2019-001466 on 11 April 2019. Downloaded from WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? Joshua P Vogel, 1,2 Myfanwy Williams,3 Ioannis Gallos,4 Fernando Althabe,1 Olufemi T Oladapo1 To cite: Vogel JP, THE GLOBAL BURDEN OF POSTPARTUM trials of tranexamic acid for PPH treatment Williams M, Gallos I, et al. HAEMORRHAGE and a heat-stable formulation of carbetocin WHO recommendations on 6–12 uterotonics for postpartum Obstetric haemorrhage, especially post- for PPH prevention. The increasing haemorrhage prevention: partum haemorrhage (PPH), was responsible number of PPH prevention and management what works, and which for more than a quarter of the estimated 303 options makes it challenging for providers one?BMJ Glob Health 000 maternal deaths that occurred globally in and health system stakeholders to choose 2019;4:e001466. doi:10.1136/ 2015.1 PPH—commonly defined as a blood where and how to invest limited resources in bmjgh-2019-001466 loss of 500 mL or more within 24 hours after order to optimise health outcomes. birth—affects about 6% of all women giving Multiple uterotonics have been eval- Handling editor Seye Abimbola birth.1 Uterine atony is the most common uated for PPH prevention over the past Received 4 February 2019 cause of PPH, but it can also be caused by four decades, including oxytocin receptor Revised 10 March 2019 genital tract trauma, retained placental tissue agonists (oxytocin and carbetocin), prosta- Accepted 16 March 2019 or maternal bleeding disorders. The majority glandin analogues (misoprostol, sulprostone, of women who experience PPH have no iden- carboprost), ergot alkaloids (such as ergo- tifiable risk factor, meaning that PPH preven- metrine/methylergometrine) and combina- tion programmes rely on universal use of PPH tions of these (oxytocin plus ergometrine, © Author(s) (or their prophylaxis for all women in the immediate or oxytocin plus misoprostol).
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME PROSTIN 15M 250 microgram (µg)/mL Solution for Injection 2. QUALITATIVE AND QUANTITIATIVE COMPOSITION Each 1 mL contains 250 μg carboprost or 332 μg carboprost (as tromethamine). Excipient(s) with known effect Each 1 mL contains 9.45 mg/mL benzyl alcohol (added as preservative). For the full list of excipients, see section 6.1. 3. PHARMACEUTIAL FORM Solution for Injection. PROSTIN 15M is a clear colourless solution. 4. CLINCAL PARTICUALRS 4.1 Therapeutic indications PROSTIN 15M is indicated for the treatment of postpartum haemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of PROSTIN 15M has resulted in satisfactory control of haemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered embolic agents have contributed to the outcome. In a high proportion of cases, PROSTIN 15M used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention. 4.2 Dose and method of administration Dose An initial dose of 250 µg (1 mL) is to be given by deep intramuscular injection. In clinical trials, it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome. The need for additional injections and the interval at which these should be given can be determined only by the attending physicians as dictated by the course of clinical events.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • O SIEMSGLUSS IBERICA, S.A
    SIEMSGLUSS IBERICA, S.A. Product list G Memantine HCI Propylparaben Sodium Pharma APls Gemfibrozil Mepiramina Maleato R Gentian Powder Methoxsalen Ramipril Gentian Violet Methyl Nicotinate Ranitidin HCI Glibenclamide Methylprednisolone Base Rapamycin (Slrollrnus) Glimepiride Metimazole Resorcin A e Gluthatione reduced Metronidazol Resveratrol (Veri-Te®) 11 Alpha Hydroxyprogesterone Caffein Anhydrous Cyproterone Acetate Guaiacol Glyceril Ether Mexiletine HcI Rifampicin 17 Alpha Estradiol Calcipotriol Mieonazole Nitrate o H Roxythromycin Acetyl Salicylic Acid Canrenone Miltefosine Desonide Micronized Hydroquinone AcetylSpiramycin Cantharidin Minocycline HcI Dexamethasone BaseMicro Hyaluronic Acid Sodium Salt s Adapalene Captopril Minoxidil Seenidazol Dexamethasone Isonicotinate Miero Hydrochlorthiazide Amidopyrine Carbamazepine Mometasone Furoato Silver Sulfadiazine Dexamethasone Sodium Phosphate Hydrocortisone Acetate Micro Amikacin Sulphate Carbidopa Montelukast Sodium Simvastatine Dexketoprofen Trometamol Hydrocortisone BaseMicro Amiloride Carisoprodol Sodium Cefonicide Dextrometorphan Bromhidrate Hydroxyzine HcI N Amitriptyline HCI Carvedilol $pironolactone Micro Dextrose (Glucosa) Anhydrous N Aeetyl Glueosamine Amoxlcillin Na + Clavulonate K Cefaclor Monohidrate Sulpiride Diacethyl Naproxen Powder Ibuprofen Amoxicillin Na + Clavulonate K(5:1) Cefadroxil Compaeted Dielofenae Sodium Neutral Pellets Idebenone T Amoxicillin Trihydrate Compacted Cefalexine Monohydrate Powder Difenhydramire Nisin Taerollmus Monohydrate Imiquimod Amoxlcillln
    [Show full text]
  • RIEMSER Group International Product List
    RIEMSER Group International Product List Product Active substance Presentation Indication Product Category Channel EMB Fatol Ethambutol • POI 1g/10ml Treatment of several forms and stages of Anti-infectives Rx dihydrochloride • TAB 100mg tuberculosis • FCT 400, 500 mg Eremfat Rifampicin • GRA 1.2g/60ml Anti-infectives Rx • POI 300, 600mg Tuberculosis therapy , combination treatment of • FCT 150, 300, 450, 600 leprosy, prophylaxis for meningococcal meningitis, treatment of infections caused by nontuberculous mycobacteria Isozid Isoniazid • TAB 50, 100, 200 mg During Chemotherapy, -prophylaxis and - Anti-infectives Rx • POI 500mg prevention for / of tuberculosis Isozidcomp Isoniazid / pyridoxine • TAB 100mg / 20mg Chemotherapy, -prophylaxis and -prevention for / Anti-infectives Rx • FCT 200mg /40 mg, 300mg/60mg of Tuberculosis PAS-Fatol Sodium aminosalicylate • POI 13.49g Chemotherapy for tuberculosis, caused by Anti-infectives Rx dihydrate mycobacterium tuberculosis and mycobacterium bovis. Peteha Protionamide • FCT 250mg Treatment of tuberculosis, leprosy and diseases Anti-infectives Rx caused by so-called ubiquitours (atypical) mycobacteria Pyrafat Pyrazinamide • FCT 500mg Combination therapy for all types of tuberculosis, Anti-infectives Rx • TAB 500mg caused by mycobacterium tuberculosis, mycobacterium africanum, or mycobacterium microtti. Terizidon Terizidone • CAP 250mg Treatment of tuberculosis caused by Anti-infectives Rx mycobacterium tuberculosis Vancomycin Enterocaps Vancomycin • CAP 250 mg Treatment of certain types of bowel
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Confidential: for Review Only
    BMJ Confidential: For Review Only The risk of fall and fracture with the initiation of a prostate - selective alpha antagonist Journal: BMJ Manuscript ID: BMJ.2015.028205 Article Type: Research BMJ Journal: BMJ Date Submitted by the Author: 17-Jul-2015 Complete List of Authors: Welk, Blayne; Western University, McArthur, Eric; Institute for Clinical Evaluative Sciences,, Fraser, Lisa-Ann; Western University, Medicine Hayward, Jade; Institute for Clinical Evaluative Sciences,, Dixon, Stephanie; Institute for Clinical Evaluative Sciences,, Hwang, Joseph; Case Western Reserve University School of Medicine, Ordon, Michael; University of Toronto, Surgery (Urology) Keywords: BPH, Fall, Fracture, Alpha antgonist https://mc.manuscriptcentral.com/bmj Page 1 of 45 BMJ 1 2 The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist 3 4 1,2,3 2 4 2 5 Blayne Welk MD MSc , Eric McArthur MSc , Lisa-Ann Fraser MD MSc , Jade Hayward , 6 Stephanie Dixon MSc PhD 2,3 , Y. Joseph Hwang MSc 5, Michael Ordon MD MSc 6 7 8 1 DepartmentConfidential: of Surgery, Western University, For London Review, Ontario, Canada Only 9 2 Institute for Clinical Evaluative Sciences, London, Ontario, Canada 10 11 3 Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada 12 4 Department of Medicine, Western University, London, Ontario 13 5 MD Candidate, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA 14 6 Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada 15 16 17 Correspondence: 18 Blayne Welk, MD MSc 19 Assistant Professor, Division of Urology and Epidemiology and Biostatistics 20 Western University 21 Room B4-667 22 23 St Joseph's Health Care 24 268 Grosvenor Street London ON N6A 4V2 25 Telephone: 519 646-6367 | Fax: 519 646-6037 26 [email protected] 27 28 29 Addresses: 30 Mr McArthur: [email protected] 31 LHSC – Victoria Hospital 32 ELL-101, 800 Commissioners Rd.
    [Show full text]
  • Ergot Alkaloids As Dopamine Agonists: Comparison in Two Rodent Models
    European Journal of Pharmacology, 37 (1976) 295-302 295 © North-Holland Publishing Company, Amsterdam - Printed in The Netherlands ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS GILL ANLEZARK, CHRIS PYCOCK and BRIAN MELDRUM Department of Neurology, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, U.K. Received 18 December 1975, revised MS received 20 February 1976, accepted 26 February 1976 G. ANLEZARK, C. PYCOCK and B. MELDRUM, Ergot alkaloids as dopamine agonists: comparison in two rodent models, European J. Pharmacol. 37 (1976) 295-302. A series of ergot alkaloids, together with the DA agonists apomorphine and piribedil, were tested for protec- tive effects against audiogenic seizures in an inbred strain of mice (DBA/2) and for induction of circling behaviour in mice with unilateral destruction of one nigrostriatal DA pathway. The order of potency against audiogenic sei- zures was apomorphine> ergocornine> bromocryptine > ergometrine> LSD> methysergide > piribedil while that observed in the rotating mouse model was apomorphine> ergometrine> ergocornine> brornocryptine > piribedil. LSD caused only weak circling behaviour even when administered in high doses (> 1 mg/kg). Methyser- gide was ineffective. Prior administration of the neuroleptic agent haloperidol blocked the effect of DA agonists and of ergot alkaloids in both animal models. The possible action of ergot alkaloids as DA agonists is discussed. Ergot alkaloids Audiogenic seizures Dopamine agonists Circling behaviour 1. Introduction gic synapses, in two rodent pharmacological models. The first model studied is 'audiogen- The pharmacology of the ergot alkaloids is ic' seizures in genetically susceptible mice. complex and not well understood. Peripheral- The severity of the seizure responses to audi- ly, they act on smooth muscle as 5-hydroxy- tory stimulation can be modified by a variety tryptamine (5-HT) antagonists (Goodman and of drugs believed to act on monoaminergic Gilman, 1971) and as a-adrenergic blockers transmission in the brain (Lehmann, 1970).
    [Show full text]